A Phase III Multicenter, Open-Label Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma
Phase of Trial: Phase III
Latest Information Update: 17 May 2017
At a glance
- Drugs Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
- Indications Diffuse large B cell lymphoma; Follicular lymphoma
- Focus Adverse reactions
- Acronyms RATE
- Sponsors Genentech
- 10 Jun 2017 Biomarkers information updated
- 22 Dec 2011 Planned end date changed from 1 Feb 2011 to 1 May 2011 as reported by ClinicalTrials.gov.
- 11 Dec 2011 Status changed from active, no longer recruiting to completed; results have been reported at the 53rd Annual Meeting and Exposition of the American Society of Hematology .